

July 23, 1964

Leonard B. Achor, Ph.D., M.D.  
Medical Department  
Sandoz Pharmaceuticals  
Hanover, New Jersey

Dear Dr. Achor:

During the past week, we have crystalized our research program in the analysis of the EEG and behavioral changes with thioridazine and chlordiazepoxide. When I called Dr. Henze, he was kind enough to send us samples of Mellaril (100 mg.) and corresponding placebos.

These have been compared with the capsules sent to us by Hoffman-LaRoche, and they are indistinguishable.

In reassessing our protocol, we have concluded that a greater degree of flexibility would be introduced into the program if the thioridazine capsules were made in 50 mg. strength. Can this be accomplished?

If so, we estimate that for the full study we will need 16,000 capsules of 50 mg. strength. In addition, we will need a total of 16,000 capsules of placebo, and would request Sandoz Pharmaceuticals to supply us with half that amount. Would you consider, therefore, this letter as a request for supplies of thioridazine, 50 mg. capsules, in the amount quoted above, and placebo?

We will need these supplies over a full year, and if the full amount is not available in the immediate future, we would like to receive a supply sufficient to begin the study within the next few weeks.

Thank you for your cooperation.

Sincerely yours,

Max Fink, M. D.  
Director

MF/jb

P.S. The capsules of placebo were labeled H-00185, and the capsules of Mellaril as H-00267 (100 mg. thioridazine hydrochloride).